ReviewTrends in microbiology2016
Harnessing the Prokaryotic Adaptive Immune System as a Eukaryotic Antiviral Defense.
Review in Trends in microbiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Genome-editing approaches and applications: a brief review on CRISPR technology and its role in cancer.3 Biotech · 2021Review
- Engineering plant virus resistance: from RNA silencing to genome editing strategies.Plant biotechnology journal · 2020Review
- Production of CFTR-ΔF508 Rabbits.Frontiers in genetics · 2020Article
- CRISPR-Cas13d mediates robust RNA virus interference in plants.Genome biology · 2019Article
- HIV-1 Employs Multiple Mechanisms To Resist Cas9/Single Guide RNA Targeting the Viral Primer Binding Site.Journal of virology · 2018Article
- Establishing RNA virus resistance in plants by harnessing CRISPR immune system.Plant biotechnology journal · 2018Article
- CRISPR/Cas9-mediated resistance to cauliflower mosaic virus.Plant direct · 2018Article
- Antiviral Defenses in Plants through Genome Editing.Frontiers in microbiology · 2017Review
- Gene Editing Approaches against Viral Infections and Strategy to Prevent Occurrence of Viral Escape.PLoS pathogens · 2016Review
- CRISPR/Cas9: a double-edged sword when used to combat HIV infection.Retrovirology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Clustered, regularly interspaced, short palindromic repeats - CRISPR-associated (CRISPR-Cas) systems - are sequence-specific RNA-directed endonuclease complexes that bind and cleave nucleic acids. These systems evolved within prokaryotes as adaptive immune defenses to target and degrade nucleic acids derived from bacteriophages and other foreign genetic elements. The antiviral function of these systems has now been exploited to combat eukaryotic viruses throughout the viral life cycle. Here we discuss current advances in CRISPR-Cas9 technology as a eukaryotic antiviral defense.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.